Page last updated: 2024-09-03

gefitinib and glutamic acid

gefitinib has been researched along with glutamic acid in 3 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(glutamic acid)
Trials
(glutamic acid)
Recent Studies (post-2010) (glutamic acid)
5,2315662,91941,75745212,876

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)glutamic acid (IC50)
Chain A, GLUTAMATE RECEPTOR SUBUNIT 2Rattus norvegicus (Norway rat)0.821
Chain A, Glutamate Receptor Subunit 2Rattus norvegicus (Norway rat)0.821
Chain B, Glutamate Receptor Subunit 2Rattus norvegicus (Norway rat)0.821
Metabotropic glutamate receptor 8Homo sapiens (human)0.0057
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)0.07
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)0.07
Glutamate receptor 1Rattus norvegicus (Norway rat)0.5885
Glutamate receptor 2Rattus norvegicus (Norway rat)0.5885
Glutamate receptor 3Rattus norvegicus (Norway rat)0.5885
Glutamate receptor 4Rattus norvegicus (Norway rat)0.5885
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)0.38
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)0.1533
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)0.38
Glutamate receptor 1Homo sapiens (human)0.613
Glutamate receptor 2Homo sapiens (human)0.613
Glutamate receptor 3Homo sapiens (human)0.613
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)0.38
Excitatory amino acid transporter 1Homo sapiens (human)207
Glutamate receptor 4Homo sapiens (human)0.613
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)0.1533
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)0.1533
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)0.1533
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)0.38
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)0.07
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)0.07
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)0.07
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)0.07
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)0.1533
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)0.38
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)0.07
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)0.1533
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)0.1533

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H1
Carrillo, V; Dubisz, E; Gulzar, H; Mahajan, SS; Morgan, D; Yelskaya, Z1

Trials

1 trial(s) available for gefitinib and glutamic acid

ArticleYear
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Glutamic Acid; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Quinazolines; Treatment Outcome

2006

Other Studies

2 other study(ies) available for gefitinib and glutamic acid

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Glioblastoma; Glutamic Acid; Humans; Quinazolines; Riluzole; Xanthenes

2013